Sanofi is overhauling its executive leadership structure, creating a streamlined Executive Committee designed to sharpen decision-making, strengthen business execution and position the pharmaceutical giant for its next phase of growth.

 

The new leadership team, effective September 1, 2026, will bring together senior executives overseeing Sanofi’s core businesses, research and development, manufacturing and critical global functions.

 

The revamped Executive Committee will include: François Roger, Executive Vice President, Finance; Paulo Fontoura, Executive Vice President, Head of Research & Development; Manuela Buxo, Executive Vice President, Specialty Care; Thomas Triomphe, Executive Vice President, Vaccines; Thomas Grenier, Executive Vice President, General Medicines; Brendan O’Callaghan, Executive Vice President, Manufacturing & Supply; Jamie Haney, Executive Vice President, General Counsel; Véronique Jaillet, Executive Vice President, Chief People Officer, ad interim.

 

Sanofi said Emmanuel Frenehard, Head of Digital, and Audrey Duval, Head of Corporate Affairs and President of Sanofi France, will continue reporting directly to Chief Executive Officer Belén Garijo.

 

The changes also expand the responsibilities of several executives. Madeleine Roach, currently Head of Business Operations, will become President and Country Lead for Sanofi Germany, Switzerland and Austria. Her current business operations responsibilities will move into the Finance organization, which will take on an expanded role including Global Partnering and Business Development to create a more integrated approach to partnerships, business development and mergers and acquisitions.

 

Thomas Triomphe will additionally oversee China while continuing as Executive Vice President, Vaccines.

 

Commenting on the changes, Sanofi CEO Belén Garijo said: "This Executive Committee brings together experienced professionals who will work together to help shape our future direction, make disciplined choices, execute them with focus, and ensure we continue to deliver for our patients, our people and all our stakeholders. 

 

"I would like to thank all those who have contributed to Sanofi’s success and those who will continue to shape its future. I am deeply grateful for their leadership, commitment and dedication, and I wish everyone every success for the future."

 

Sanofi said the leadership evolution reflects its focus on operational discipline, scientific innovation and delivering long-term value for patients, employees and stakeholders as it enters its next strategic chapter.